JP2022137237A5 - - Google Patents

Download PDF

Info

Publication number
JP2022137237A5
JP2022137237A5 JP2022113736A JP2022113736A JP2022137237A5 JP 2022137237 A5 JP2022137237 A5 JP 2022137237A5 JP 2022113736 A JP2022113736 A JP 2022113736A JP 2022113736 A JP2022113736 A JP 2022113736A JP 2022137237 A5 JP2022137237 A5 JP 2022137237A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
salt
salt according
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022113736A
Other languages
English (en)
Japanese (ja)
Other versions
JP7288540B2 (ja
JP2022137237A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/014671 external-priority patent/WO2020154447A1/en
Application filed filed Critical
Publication of JP2022137237A publication Critical patent/JP2022137237A/ja
Publication of JP2022137237A5 publication Critical patent/JP2022137237A5/ja
Priority to JP2023086862A priority Critical patent/JP7525693B2/ja
Application granted granted Critical
Publication of JP7288540B2 publication Critical patent/JP7288540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022113736A 2019-01-22 2022-07-15 Mtorcモジュレーターおよびその使用 Active JP7288540B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023086862A JP7525693B2 (ja) 2019-01-22 2023-05-26 Mtorcモジュレーターおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962795482P 2019-01-22 2019-01-22
US62/795,482 2019-01-22
PCT/US2020/014671 WO2020154447A1 (en) 2019-01-22 2020-01-22 Mtorc modulators and uses thereof
JP2021543495A JP7061236B2 (ja) 2019-01-22 2020-01-22 Mtorcモジュレーターおよびその使用
JP2022067435A JP7108804B2 (ja) 2019-01-22 2022-04-15 Mtorcモジュレーターおよびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022067435A Division JP7108804B2 (ja) 2019-01-22 2022-04-15 Mtorcモジュレーターおよびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023086862A Division JP7525693B2 (ja) 2019-01-22 2023-05-26 Mtorcモジュレーターおよびその使用

Publications (3)

Publication Number Publication Date
JP2022137237A JP2022137237A (ja) 2022-09-21
JP2022137237A5 true JP2022137237A5 (enExample) 2023-01-20
JP7288540B2 JP7288540B2 (ja) 2023-06-07

Family

ID=71737003

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021543495A Active JP7061236B2 (ja) 2019-01-22 2020-01-22 Mtorcモジュレーターおよびその使用
JP2022067435A Active JP7108804B2 (ja) 2019-01-22 2022-04-15 Mtorcモジュレーターおよびその使用
JP2022113736A Active JP7288540B2 (ja) 2019-01-22 2022-07-15 Mtorcモジュレーターおよびその使用
JP2023086862A Active JP7525693B2 (ja) 2019-01-22 2023-05-26 Mtorcモジュレーターおよびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021543495A Active JP7061236B2 (ja) 2019-01-22 2020-01-22 Mtorcモジュレーターおよびその使用
JP2022067435A Active JP7108804B2 (ja) 2019-01-22 2022-04-15 Mtorcモジュレーターおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023086862A Active JP7525693B2 (ja) 2019-01-22 2023-05-26 Mtorcモジュレーターおよびその使用

Country Status (14)

Country Link
US (4) US11230557B2 (enExample)
EP (2) EP3914245A4 (enExample)
JP (4) JP7061236B2 (enExample)
KR (2) KR102643707B1 (enExample)
CN (3) CN116947884B (enExample)
AU (3) AU2020210921B2 (enExample)
BR (1) BR112021014479A2 (enExample)
CA (2) CA3236782A1 (enExample)
EA (1) EA202191983A1 (enExample)
GB (3) GB2586113B (enExample)
IL (2) IL315399A (enExample)
MX (2) MX2021008777A (enExample)
WO (1) WO2020154447A1 (enExample)
ZA (3) ZA202105847B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092692A1 (ru) 2018-06-15 2021-04-21 Навитор Фармасьютикалз, Инк. Аналоги рапамицина и их применения
IL315399A (en) 2019-01-22 2024-11-01 Aeovian Pharmaceuticals Inc Mtorc modulators and uses thereof
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
AU2021241718B2 (en) 2020-03-27 2025-03-27 Aeovian Pharmaceuticals, Inc. mTORC1 modulators and uses thereof
EP4185590A2 (en) * 2020-07-21 2023-05-31 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
US20220267352A1 (en) * 2021-01-22 2022-08-25 Anakuria Therapeutics, Inc. Rapamycin analogs and uses thereof
CN116917294A (zh) * 2021-01-22 2023-10-20 詹森药业有限公司 雷帕霉素类似物及其用途
CN119836424A (zh) * 2022-09-30 2025-04-15 百多力股份公司 依维莫司环状烃酯的合成与表征

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
CH677886A5 (enExample) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
JP3745772B2 (ja) * 1993-12-17 2006-02-15 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤として有用なラパマイシン誘導体
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
SK182498A3 (en) 1996-07-05 2000-05-16 Biotica Tech Ltd Erythromycins and process for their preparation
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
CA2405958C (en) 2000-04-13 2011-08-09 Biotica Technology Limited Hybrid glycosylated products and their production and use
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
GB0128680D0 (en) 2001-11-29 2002-01-23 Biotica Tech Ltd Hybrid glycosylated products and their production and use
BR0312691A (pt) 2002-07-16 2005-05-10 Biotica Tech Ltd Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
AR052269A1 (es) * 2004-12-20 2007-03-07 Wyeth Corp Analogos de rapamicina, un proceso para su elaboracion y los usos de los mismos en la preparacion de un medicamento para el tratamiento de trastornos neurologicos, proliferativos e inflamatorios.
WO2006136175A2 (en) * 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
GB0601406D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
CA2743006C (en) 2008-11-11 2016-02-09 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
CN102731527A (zh) 2012-07-12 2012-10-17 浙江医药股份有限公司新昌制药厂 一种西罗莫司42-醚衍生物的合成方法
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
WO2016040806A1 (en) * 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
CN104341434B (zh) 2014-10-16 2016-04-06 福建省微生物研究所 取代的雷帕霉素三氮唑衍生物和用途
WO2017040341A1 (en) * 2015-08-28 2017-03-09 Buck Institute For Research On Aging RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
EP3345601A4 (en) * 2015-09-03 2019-05-15 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION CONTAINING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017044720A1 (en) * 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
EA202092692A1 (ru) 2018-06-15 2021-04-21 Навитор Фармасьютикалз, Инк. Аналоги рапамицина и их применения
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
MX2021007247A (es) 2018-12-18 2021-07-15 Novartis Ag Derivados de rapamicina.
IL315399A (en) 2019-01-22 2024-11-01 Aeovian Pharmaceuticals Inc Mtorc modulators and uses thereof
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
AU2021241718B2 (en) 2020-03-27 2025-03-27 Aeovian Pharmaceuticals, Inc. mTORC1 modulators and uses thereof
EP4185590A2 (en) 2020-07-21 2023-05-31 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
US20220267352A1 (en) 2021-01-22 2022-08-25 Anakuria Therapeutics, Inc. Rapamycin analogs and uses thereof

Similar Documents

Publication Publication Date Title
JP2022137237A5 (enExample)
ES2922973T1 (es) Peptidos funcionalizados como agentes antivirales
JP2010501584A5 (enExample)
CN111868026A (zh) 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途
JPWO2022177917A5 (enExample)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2012505836A5 (enExample)
CN115038694A (zh) 一种异吲哚啉衍生物、其药物组合物及应用
RU2005128190A (ru) Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации
JP2006528643A5 (enExample)
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
JP2013532652A5 (enExample)
JPWO2020123827A5 (enExample)
JP2021046404A5 (enExample)
JP2020075939A5 (enExample)
JP2008536833A5 (enExample)
JP2007514691A5 (enExample)
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
JPWO2021030555A5 (enExample)
JP2005526773A5 (enExample)
JPWO2022251502A5 (enExample)
JPWO2020132504A5 (enExample)
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JPWO2023072257A5 (enExample)
JPWO2023072240A5 (enExample)